TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12811500

Group type: EXPERIMENTAL
Intervention: Trospium chloride (20 mg twice daily)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Oxybutynin (5 mg twice daily)
Number of subjects: 358
Study: 10743692

Group type: COMPARATOR
Intervention: Systemic venous drainage (SV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Portal venous drainage (PV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (SV and PV)
Number of subjects: 30
Study: 1463527

Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg b.i.d.)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Amoxicillin (500 mg t.i.d.)
Number of subjects: 336
Study: 6509782

Group type: EXPERIMENTAL
Intervention: Dopamine receptor blockade (domperidone 10 mg i.v.) in acromegalic subjects
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dopamine receptor blockade (domperidone 10 mg i.v.) in normal controls
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intramuscular growth hormone (three injections of 4 IU) before domperidone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (equivalent volume) before domperidone
Number of subjects: 15
Study: 30769128

Group type: EXPERIMENTAL
Intervention: Real rTMS (20 Hz, double cone coil over vertex)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 31
Study: 30083962

Group type: EXPERIMENTAL
Intervention: tivantinib 360 mg PO BID
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 27234001

Group type: EXPERIMENTAL
Intervention: Can Do Treatment (CDT)
Number of subjects: 140
Study: 25142708

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 7112

Group type: COMPARATOR
Intervention: No nitrous oxide
Number of subjects: 7112
Study: 23113512

Group type: EXPERIMENTAL
Intervention: Thulium laser vaporesection of the prostate
Number of subjects: 98

Group type: COMPARATOR
Intervention: Transurethral electrovaporization of the prostate
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 98
Study: 20420991

Group type: EXPERIMENTAL
Intervention: Standard care plus rocking-chair intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 66
Study: 18036467

Group type: EXPERIMENTAL
Intervention: One-on-one coaching by an opinion leader
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6
Study: 16240061

Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction (RY)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Billroth I reconstruction (B-I)
Number of subjects: 50
Study: 12038883

Group type: EXPERIMENTAL
Intervention: Community-based family-support intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study: 8951481

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 57

Group type: COMPARATOR
Intervention: External radiation therapy
Number of subjects: 57
Study: 1916523

Group type: EXPERIMENTAL
Intervention: Real vibro-acoustic stimulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 25
Study: 7128259

Group type: EXPERIMENTAL
Intervention: Intervention group (routine well-child care plus discussions regarding infant social development)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Attention control group (routine well-child care plus discussions regarding accident prevention and nutrition)
Number of subjects: 32
Study: 31773110

Group type: EXPERIMENTAL
Intervention: Isometric rehabilitation protocol augmented with the Accelerated Recovery Performance trainer protocol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Isometric rehabilitation protocol alone
Number of subjects: 25
Study: 28199397

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide/timolol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral acetazolamide and topical dexamethasone
Number of subjects: 62
Study: 26757325

Group type: EXPERIMENTAL
Intervention: Denzir (DZ)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: In-Ceram Zirconia (InZ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both groups (DZ and InZ)
Number of subjects: 18
Study: 24456143

Group type: COMPARATOR
Intervention: Post-fatigue laser treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pre-fatigue laser treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study: 22925276

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 21134997

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily for 12 weeks
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 431
Study: 17166314

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 0
Study: 14738324

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open cholecystectomy (OC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative period
Number of subjects: 0
Study: 11872510

Group type: EXPERIMENTAL
Intervention: Brief behavioural, interpersonal, cognitive, problem-solving and other psychotherapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 9500307

Group type: EXPERIMENTAL
Intervention: Expectancy manipulation (told alcohol would impair task performance)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Expectancy manipulation (told alcohol had no effect on performance)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Expectancy manipulation (effects of alcohol were unknown)
Number of subjects: 120
Study: 7651472

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 85
Study: 1669525

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Sodium restriction
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 2182
Study: 6893692

Group type: COMPARATOR
Intervention: Molsidomine (M) 4 mg, single dose
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Molsidomine (M), prolonged treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Molsidomine (M), single dose
Number of subjects: 38
Study: 30921748

Group type: EXPERIMENTAL
Intervention: Brief cognitive therapies
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Childhood trauma scores
Number of subjects: 61
Study: 27886976

Group type: EXPERIMENTAL
Intervention: Inhaled allergen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE) and allergen co-exposure
Number of subjects: 18

Group type: COMPARATOR
Intervention: Filtered air followed by instilled allergen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Serum leptin and resistin
Number of subjects: 18
Study: 25262100

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Water Immersion (WI)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 576
Study: 23322203

Group type: EXPERIMENTAL
Intervention: Diagnostic procedures for women aged 50-59
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostic procedures for women aged 40-49
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transition rates for women aged 40-49
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transition rates for women aged 50-59
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age as a risk factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factors for women aged 40-49
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factors for women aged 50-59
Number of subjects: 0
Study: 21335940

Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization
Number of subjects: 126

Group type: COMPARATOR
Intervention: Transurethral catheterization
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 126
Study: 19587249

Group type: EXPERIMENTAL
Intervention: Chart reminder plus mailed patient education (CR+PtEd)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Chart reminder alone (CR)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 204
Study: 17349495

Group type: EXPERIMENTAL
Intervention: Massage and acupuncture
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study: 14981009

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol/kg per minute) for 72 hours
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 21
Study: 11316375

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg + Relapse Prevention Therapy (RP)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Naltrexone 0 mg + Relapse Prevention Therapy (RP)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Naltrexone 50 mg + Drug Counseling
Number of subjects: 85

Group type: COMPARATOR
Intervention: Naltrexone 0 mg + Drug Counseling
Number of subjects: 85
Study: 9868707

Group type: EXPERIMENTAL
Intervention: 2 mg/kg MDE
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7980370

Group type: EXPERIMENTAL
Intervention: Self-Control over the specimen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Instructions to attend closely to the features of the specimen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Instructions to attend closely to the specimen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Partner-Control over the specimen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Instructions to attend closely to one's bodily fear reactions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Instructions to attend to one's bodily reactions
Number of subjects: 16
Study: 2658525

Group type: EXPERIMENTAL
Intervention: Penbutolol 10 mg/day
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Penbutolol 20 mg/day
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg/day
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 901695

Group type: EXPERIMENTAL
Intervention: 25 mg metoprolol tartrate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol tartrate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 6
Study: 31025258

Group type: EXPERIMENTAL
Intervention: Continuous infusion of rocuronium 0.6 mg·kg−1·hr−1
Number of subjects: 0

Group type: COMPARATOR
Intervention: NaCl 0.9% (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (NaCl 0.9%)
Number of subjects: 0
Study: 29178954

Group type: EXPERIMENTAL
Intervention: Colloidal silver (CS) nasal spray, administered twice daily for six weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline nasal spray, administered twice daily for six weeks
Number of subjects: 20
Study: 25467016

Group type: EXPERIMENTAL
Intervention: Lapatinib (1000 mg orally daily)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Trastuzumab + Lapatinib (at the same doses)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study: 23796741

Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 1980

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1980
Study: 21153021

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg infused once yearly
Number of subjects: 2127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127

Group type: EXPERIMENTAL
Intervention: NSAID use
Number of subjects: 2127
Study: 18294736

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) added to approved AD therapies for 6 months, then discontinued, and resumed for another 9 months
Number of subjects: 8
Study: 18028126

Group type: EXPERIMENTAL
Intervention: Topical recombinant human acidic fibroblast growth factor (rh‐aFGF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15040968

Group type: EXPERIMENTAL
Intervention: Insidious onset neck pain
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Whiplash injury neck pain
Number of subjects: 75

Group type: COMPARATOR
Intervention: Asymptomatic control subjects
Number of subjects: 75
Study: 11772241

Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid (ALA) in photodynamic therapy (PDT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid (ALA) as a photosensitiser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALA-induced porphyrins fluorescence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALA treatment for non-tumoural applications
Number of subjects: 0
Study: 9133891

Group type: EXPERIMENTAL
Intervention: Crude peanut oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Refined peanut oil
Number of subjects: 60
Study: 7909853

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate (42 micrograms inhaled twice daily)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Albuterol (180 micrograms inhaled four times daily)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo (four times a day)
Number of subjects: 322
Study: 3630820

Group type: EXPERIMENTAL
Intervention: Nova-T-PP
Number of subjects: 412

Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 412
Study: 30098961

Group type: EXPERIMENTAL
Intervention: 400/200 eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) fish oil at 2 g
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Almost pure EPA at 2 g
Number of subjects: 108

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 108
Study: 26556736

Group type: EXPERIMENTAL
Intervention: MK-5442 (5, 7.5, 10, or 15 mg daily)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: MK-5442 (10 mg)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526

Group type: COMPARATOR
Intervention: ALN 70 mg weekly
Number of subjects: 526
Study: 25662545

Group type: EXPERIMENTAL
Intervention: Glucosamine (1500 mg) and Chondroitin (1200 mg) combination
Number of subjects: 31

Group type: COMPARATOR
Intervention: Tramadol HCl (50 mg, twice daily)
Number of subjects: 31
Study: 22994907

Group type: EXPERIMENTAL
Intervention: Cervical OMT
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Time control
Number of subjects: 19
Study: 20669577

Group type: EXPERIMENTAL
Intervention: Needle warming therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Electroacupuncture treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Body acupuncture treatment
Number of subjects: 120
Study: 18675854

Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Exenatide (5 and 10 microg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 17
Study: 16639670

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: POAG
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: PSXG
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: NTG
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Stage 0 GONHA
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Stages 1 to 4 GONHA
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Stage 1 GONHA
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Stage 2 GONHA
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Stages 3 and 4 GONHA
Number of subjects: 281
Study: 14616152

Group type: EXPERIMENTAL
Intervention: Rabeprazole (RB) 20 mg/d in the evening (p.m.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rabeprazole (RB) 20 mg/d in the morning (a.m.)
Number of subjects: 20
Study: 11062356

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo plus 500 mg calcium supplement
Number of subjects: 46
Study: 8629588

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg/day orally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control conditions (normal volunteers)
Number of subjects: 10
Study: 1599888

Group type: EXPERIMENTAL
Intervention: 25 mg meperidine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 12.5 mg bupivacaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 25 mg meperidine plus 12.5 mg bupivacaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 25 mg bupivacaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 37.5 mg bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neonatal neurologic and adaptive capacity scores
Number of subjects: 100
Study: 4054206

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 6
Study: 29792370

Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg plus standard of care (SoC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo plus standard of care (SoC)
Number of subjects: 60
Study: 29979143

Group type: EXPERIMENTAL
Intervention: SMARTgirl HIV prevention programme for ≥ 6 months
Number of subjects: 596

Group type: COMPARATOR
Intervention: No living children
Number of subjects: 596

Group type: COMPARATOR
Intervention: Recent food insecurity
Number of subjects: 596
Study: 27338954

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Improved fitness
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Reduced dietary sodium
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Adherence to DASH diet
Number of subjects: 144
Study: 24552524

Group type: EXPERIMENTAL
Intervention: Compression-only CPR training (45-minute program)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Conventional CPR training (180-minute program)
Number of subjects: 146
Study: 22440488

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg, 3 times daily, starting 6 hours before ascent
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 19341510

Group type: EXPERIMENTAL
Intervention: Sertraline (flexible dosages up to 200 mg/d)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy (one individual session and nine group sessions per 90 min)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Guided self-help group (control condition)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Patients' choice arm (sertraline or cognitive-behavioural group therapy)
Number of subjects: 368
Study: 17493418

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d)
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Simvastatin (20 mg/d)
Number of subjects: 1632

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1632
Study: 16767609

Group type: EXPERIMENTAL
Intervention: Light Load (1.1 kg weight on each ankle)
Number of subjects: 85

Group type: COMPARATOR
Intervention: No Load (no external load)
Number of subjects: 85
Study: 14558586

Group type: EXPERIMENTAL
Intervention: X‐Tip intraosseous technique
Number of subjects: 41

Group type: COMPARATOR
Intervention: Stabident intraosseous technique
Number of subjects: 41
Study: 11154053

Group type: EXPERIMENTAL
Intervention: Sheng-ji-san (SJS) treatment combined with routine medical care
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine medical care
Number of subjects: 32
Study: 9238897

Group type: EXPERIMENTAL
Intervention: NaF dentifrice containing 5.0% pyrophosphate (Crest Tartar Control)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: NaF dentifrice containing 5.0% pyrophosphate plus 0.28% triclosan (antimicrobial)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Control dentifrice (NaF only, Crest)
Number of subjects: 346
Study: 1630773

Group type: EXPERIMENTAL
Intervention: Zonal-progressive multifocal IOL
Number of subjects: 62

Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 62
Study: 6149535

Group type: EXPERIMENTAL
Intervention: Almitrine (1.5 mg/kg orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30095981

Group type: EXPERIMENTAL
Intervention: Bimagrumab 30 mg/kg intravenously
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 27816115

Group type: EXPERIMENTAL
Intervention: Serum Chloride levels measured at randomization and during hospitalization
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Chloride change
Number of subjects: 358
Study: 26978497

Group type: EXPERIMENTAL
Intervention: Nonspecific cytoprotective therapy (cytoflavin)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 266
Study: 24337064

Group type: EXPERIMENTAL
Intervention: Risperidone treatment for 6 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 62
Study: 21782166

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg/day for 5 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Raloxifene (R) 100 mg/day for 5 days
Number of subjects: 82
Study: 19103217

Group type: EXPERIMENTAL
Intervention: Different spatial patterns (square, horizontal line, vertical line, T-shape, random shape, no local grouping)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contrast-polarity information (interaction of the On and Off pathways)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-frame motion sequence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Geometric conditions
Number of subjects: 0